Optimizing Outcomes in Patients with PAD after Revascularization

Jan 4, 2022 | PAD

2) The @cardiomet_ce program is supported by educational grants from AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals Inc and Eli Lilly Company, Bristol Myers Squibb & its Alliance partner Pfizer Inc, Chiesi, & Esperion. This program is intended for...

Best Medical Management after Lower Extremity Revascularization for Symptomatic #PAD

Jul 22, 2021 | PAD

Shout outs to @GBarnesMD @DLBHATTMD @cpcannon @MichaelJBlaha @CarlosMenaYale @JudithLin4 @JRUNMD @cmaflah @GaryRaskob @ShariqShamimMD and a reminder that past programs–still available for credit–can be found at https://t.co/vyVIMA8cMd— cardio-met...

A Case-Based Program on Evidence-Based Management of PAD

Apr 15, 2021 | PAD

1) Welcome to our accredited tweetorial on #PAD ! Expert faculty @JoshuaBeckmanMD. Earn 0.5h CME/CE credit by following this thread. Supported by Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. #cardiotwitter @MedTweetorials @GameofAcademics @CMichaelGibson—...

Initiating New Anti-thrombotic Therapy into the Treatment Regimen of a Patient with PAD

Mar 11, 2021 | PAD

2) Accredited for 0.5 credits by @academiccme: physicians, nurses, pharmacists! Expert faculty @dlbhattmd. Supported by Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. Follow this thread for credit. #cardiotwitter #medtwitter— cardio-met (@cardiomet_CE) March 8, 2021...